지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 1,153 - 1,163 (11page)
이용수
초록· 키워드
오류제보하기
Purpose Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment ( third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.
목차
등록된 정보가 없습니다.
참고문헌 (18)
참고문헌 신청
Bellet M / 2016 / Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxife
Blamey RW / 1992 / Goserelin depot in the treatment of premenopausal advanced breast cancer / Eur J Cancer 28A : 810 ~ 814
Boccardo F / 1994 / Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer : results of a multicentric Italia
Carlson RW / 2010 / Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women / J
Forward DP / 2004 / Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer / Br J Cancer 90 : 59
Blamey RW / 1992 / Goserelin depot in the treatment of premenopausal advanced breast cancer / Eur J Cancer 28A : 810 ~ 814
Boccardo F / 1994 / Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer : results of a multicentric Italia
Carlson RW / 2010 / Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women / J
Forward DP / 2004 / Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer / Br J Cancer 90 : 59
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty
Clinical and Experimental Pediatrics
2015 .01
-
Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
Annals of Pediatirc Endocrinology & Metabolism
2021 .09
-
The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study
Journal of Korean Medical Science
2020 .01
-
Comparison of the clinical outcome of frozen-thawed embryo transfer with and without pretreatment with a gonadotropin-releasing hormone agonist
Obstetrics & Gynecology Science
2018 .01
-
Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy
Annals of Pediatirc Endocrinology & Metabolism
2019 .01
-
의학전문대학원생의 임상추론 능력 파악을 위한 수정간이구조화관찰법의 효과
의료커뮤니케이션
2016 .01
-
Efficacy of an Aromatase Inhibitor Plus a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients with Hormone Receptor-positive Metastatic Breast Cancer
대한임상종양학회 학술대회지
2015 .02
-
Association between different dual trigger dosages and in vitro fertilization results in patients with patientoriented strategies encompassing individualized oocyte number group IV
Obstetrics & Gynecology Science
2022 .03
-
A Study on Dietary Habits and Lifestyle of Girls with PrecociousPuberty
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
Cancer Research and Treatment
2016 .01
-
Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty
Annals of Pediatirc Endocrinology & Metabolism
2017 .01
-
Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone- Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer
Journal of Breast Disease
2018 .01
-
Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy
Annals of Pediatirc Endocrinology & Metabolism
2020 .01
-
Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
Annals of Pediatirc Endocrinology & Metabolism
2017 .01
-
Oncology Efficacy of Gonadotropin-Releasing Hormone Agonist in Hormone Receptor-Positive Very Young Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2018 .11
-
Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty
Annals of Pediatirc Endocrinology & Metabolism
2021 .09
-
Does coronavirus disease 2019 affect body mass index of children and adolescents who visited a growth clinic in South Korea?: a single-center study
Annals of Pediatirc Endocrinology & Metabolism
2022 .03
-
The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty
Annals of Pediatirc Endocrinology & Metabolism
2017 .01
-
Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
전이성 유방암의 호르몬 치료
대한내과학회지
2017 .06
이 논문의 저자 정보
최근 본 자료
댓글(0)
0